### External Environment of Pharmaceutical Industry

#### Rapidly-aging global society
- Increasing, but increasingly segmented, medical needs
- Increased expectations for efficacy and safety of new drugs
- Growing expectations healthy life expectancy
- Increasing trends toward self medication

#### Expanding range of therapeutic agents to include new drug discovery paradigms
- Applying innovative technologies such as iPS cells to enable regenerative medicine and new drug discovery
- Shifting to precision medicine, targeting therapy based on individual factors such as genetic background, environment and lifestyle

#### Changes in the Japanese and global pharmaceutical markets
- Developed countries: Financial pressure on health insurance, controversy around high drug prices, both adding to pricing pressure
- Emerging countries: Slowdown in economic growth, political risk to drug pricing, intellectual property risk

#### Enhanced expectations for the pharmaceutical industry in Japan
- Contribution to economic growth as a high value-added industry
- Strategic industry supported by the government

* An emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person
Stages 1 through 3: FY2000 - FY2013

1st stage: Laying the foundation (FY2000 - 2004)
- Focused specifically on the prescription drug business
- Established infrastructure for global development

2nd stage: Accelerating toward significant strides (FY2005 - 2009)
- Focused R&D efforts on priority therapeutic areas (infectious diseases, pain, and metabolic syndrome)
- Acquired US-based Sciele Pharma, Inc.

3rd stage: SONG for the Real Growth (FY2010 - 2013)
- Shifted US business focus from 505(b)2s to innovative drugs while stabilizing business performance, and established business footholds in EU and China
- In Japan, increased sales of eight strategic products, and expanded their share of Rx sales
- Launched Tivicay® and Osphena®
- Established a new business scheme for HIV integrase inhibitor franchise
- Modified the Crestor® royalty structure
New arrangement with ViiV Healthcare Ltd. (announced on Oct. 29, 2012)

- JV’s rights* to the integrase inhibitor franchise products were transferred to ViiV, and Shionogi became a 10% shareholder with Board representation.

** JV: Shionogi-ViiV Healthcare LLC

** GSK increased from 77.4% to 78.3%, Pfizer decreased from 12.6% to 11.7%, effective on Apr. 1, 2014.
Modification of the Crestor® Royalty Structure

- New license agreement with AstraZeneca (announced on Dec. 25, 2013)

### Global Sales and Royalty Income

<table>
<thead>
<tr>
<th></th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crestor® Global sales (B$)</td>
<td>5.7</td>
<td>6.6</td>
<td>6.3</td>
<td>5.6</td>
<td>5.5</td>
</tr>
<tr>
<td>Royalty income (M$*)</td>
<td>729</td>
<td>810</td>
<td>791</td>
<td>682</td>
<td>456</td>
</tr>
</tbody>
</table>

* Calculated based on our exchange rate
SHIONOGI’s Growth Strategy toward 2020

New Medium-Term Business Plan of SHIONOGI

**Shionogi Growth Strategy 2020**
*(SGS2020)*

*(Announced on Mar. 28, 2014)*

Our Vision

Grow as a drug discovery-based pharmaceutical company
Sales and therapeutic areas chosen based on our strengths and the needs of society

**Needs of a rapidly-aging society**
(extension of HALE, support return to productive activities)

**Sales area**
- Japanese market
- US market

**Therapeutic area (pipeline)**
- Small molecule drug discovery
- Infectious disease
- Pain/CNS

Achieve Growth by Leveraging the Strengths of Shionogi

HALE: healthy life expectancy
**Consolidated Financial Target in SGS2020**

<table>
<thead>
<tr>
<th>R&amp;D expenses (B yen)</th>
<th>Ordinary income (B yen)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY2013* 53.6</td>
<td>Target for FY2020 100.0</td>
</tr>
<tr>
<td>Net sales (B yen)</td>
<td></td>
</tr>
<tr>
<td>FY2013 289.7</td>
<td>Target for FY2020 500.0</td>
</tr>
<tr>
<td>FY2013* 62.2</td>
<td>Target for FY2020 125.0</td>
</tr>
</tbody>
</table>

**ROE**

- FY2013* 9.2%
- Target for FY2020 15%

**Response to rapid environmental changes**

(Three-year rolling; Clarify annual results and business challenges)

* The accounting policy for R&D expenses was changed effective Apr. 1, 2014. Figures for FY2013 have been restated to reflect this change.
SGS2020 Rolling Plan (Targets for FY2017)

Clear priorities and focused resourcing

Evolution of Core Business

Shift Gears for Growth

Growth led by FIC and LIC compounds

FY2015
FY2016
FY2017
FY2018
FY2019
FY2020

Net sales 350 B yen
Ordinary income 90 B yen
ROE 12%

Net sales 500 B yen
Ordinary income 125 B yen
ROE 15%

Clarify annual results and business status in three-year rolling plans

FY2015 to FY2017: Advancing core businesses and positioning for further growth

- Maximize the value of Crestor® and Cymbalta® in Japan
- Increase revenues from Osphena® in the US
- Strengthen pipeline in our core therapeutic areas
- Develop an operating structure independent of royalty income

FIC: First-in-Class, LIC: Last-in-Class
# Revision of FY2015 Financial Forecasts

## Favorable progress toward achieving FY2017 targets

<table>
<thead>
<tr>
<th></th>
<th>FY2014 (Results)</th>
<th>FY2015 (Forecasts) Revised on Oct. 29</th>
<th>FY2017 (Targets*)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net sales</strong></td>
<td>274.0 B yen</td>
<td>296.0 → 301.5 B yen</td>
<td>350.0 B yen</td>
</tr>
<tr>
<td><strong>Cost of sales</strong></td>
<td>30 %</td>
<td>24.8 → 24.4 %</td>
<td>25 %*</td>
</tr>
<tr>
<td><strong>Ordinary income</strong></td>
<td>77.9 B yen</td>
<td>79.5 → 88.0 B yen</td>
<td>90.0 B yen</td>
</tr>
<tr>
<td><strong>ROE</strong></td>
<td>9.4 %</td>
<td>10.6 → 11.9 %</td>
<td>12.0 %</td>
</tr>
</tbody>
</table>

* Target for cost of sales for FY2020
**HIV Franchise; Triumeq® and Tivicay®**

**Demonstrated drug discovery capabilities for anti-infectives**
- Tivicay® was discovered via collaborative research and development with ViiV (former Shionogi-GlaxoSmithKline joint venture)
- Triumeq® is a single-pill regimen containing dolutegravir
  EU, Canada, Japan, etc.
- Launched by a highly experienced team at ViiV, a global specialist HIV company
- Characteristics: Oral tablet, once-daily

**Tivicay, with its Strong Efficacy and Safety Profile confirmed in Phase III/IV studies, is an important new option for all lines of HIV treatment**
- Tivicay can be used in treatment-naïve and treatment-experienced patients
- In addition to the US NIH Guidelines’ recommendation for both Triumeq® and Tivicay® plus Truvada® as the highest rating for ART-naïve patients; WHO recommended ART to be initiated in HIV patients immediately after diagnosis
HIV Integrase Inhibitor Franchise

- Development of oral fixed dose combination tablet of dolutegravir (DTG) and rilpivirine (RPV) for HIV treatment
  - Two drug combination therapy leveraging DTG’s efficacy, safety and resistance profile
  - Phase III study ongoing: Planned launch H1 2018

- Development of oral fixed dose combination tablet of DTG and lamivudine (3TC)
  - 2-drug STR for treatment in naïve and suppressed patients: Planned launch H1 2019

- Development of long-acting injectable cabotegravir (CAB)
  - CAB + RPV, treatment for HIV infection: Long-acting injectable formulation is expected to reduce the mental burden on patients who otherwise would take their anti HIV agent everyday
    - Phase IIb study ongoing: Planned Phase III start Mid-2016, launch 2019/2020
  - CAB monotherapy for HIV prevention
    - Phase IIa study ongoing: Planned Phase III start 2016, launch +2020

<table>
<thead>
<tr>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>NDA</th>
<th>Approval</th>
<th>Launch</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tivicay® (dolutegravir)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triumeq® (dolutegravir/abacavir/lamivudine)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dolutegravir + lamivudine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dolutegravir + rilpivirine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cabotegravir LA + rilpivirine LA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Out-licensed to ViiV
- Co-development of ViiV and Janssen

LA: Long acting parenteral formulation
**Sales Growth of Strategic Products in Japanese Market**

- Increase sales of eight strategic products by improving sales force impact
  - Increase profitability by deploying SG&A funds in a new way
  - Blunt the impact of NHI price revisions

![Graph showing sales growth of strategic products](image)

- **8 Strategic Products**
  - OxyContin® franchise
  - Crestor®
  - Irbetan® franchise
  - Cymbalta®
  - Finibax®
  - Differin®
  - Pirespa®
  - Rapiacta®

- **3 Key strategic products**
  - OxyContin® franchise
  - Crestor®
  - Irbetan® franchise

**Years and Sales**

- **FY2009**
  - Total: 153 (B yen)
  - Strategic: 44
  - Other: 109

- **FY2013**
  - Total: 168 (B yen)
  - Strategic: 93
  - Other: 75

- **FY2014**
  - Total: 161 (B yen)
  - Strategic: 96
  - Other: 65

- **FY2015 forecast**
  - Total: 167 (B yen)
  - Strategic: 105
  - Other: 62

**Percentages**

- **FY2009**
  - 8 strategic products: 71%
  - Other: 29%

- **FY2013**
  - 8 strategic products: 45%
  - Other: 55%

- **FY2014**
  - 8 strategic products: 41%
  - Other: 59%

- **FY2015 forecast**
  - 8 strategic products: 37%
  - Other: 63%
## Pipeline for Future Growth in the Japanese Domestic Market

<table>
<thead>
<tr>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>NDA</th>
<th>Approval</th>
<th>Launch</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actair® House Dust Mite Sublingual Tablets (Allergic rhinitis caused by house-dust mite allergen)</td>
<td></td>
<td></td>
<td></td>
<td>Approved: Mar. 2015</td>
<td></td>
</tr>
<tr>
<td>Mulpleta® (lusutrombopag ) (Thrombocytopenia)</td>
<td></td>
<td></td>
<td></td>
<td>Approved: Sep. 2015</td>
<td></td>
</tr>
<tr>
<td>Cymbalta® (Pain associated with chronic low back pain)</td>
<td></td>
<td></td>
<td>NDA submission (in preparation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S-877503 (ADHD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cymbalta® (Pain associated with osteoarthritis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naldemedine (S-297995) (Alleviation of opioid-induced adverse effects)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S-877489 (ADHD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OxyContin® (Moderate to severe chronic pain; tamper resistant formulation)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S-649266 (Severe gram-negative infections)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S-033188 (Influenza virus infection)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S-237648 (Obesity)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Steady series of launches in the Japanese market**

- Infectious disease
- Pain/CNS
- Metabolic syndrome
- Frontier
Pain/CNS: Naldemedine

**Mechanism of action of naldemedine on opioid induced constipation (OIC)**

Opioids provide analgesia as well as act on peripheral opioid receptors. The latter action in the GI tract causes dysmotility and constipation.

Naldemedine is a PAMORA that targets peripheral mu-opioid receptors. In the GI tract, this directly blocks opioid effects on the bowel.

**Naldemedine market**
- Global opioid market*: US$14.8B
- Chronic opioid patients 70M (US, UK, Germany, France and Canada)
- 40~90%** of chronic opioid patients experience OIC, and <50% of patients taking laxative report satisfactory results

---

<table>
<thead>
<tr>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>NDA</th>
<th>Approval</th>
<th>Launch</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naldemedine (Alleviation of opioid-induced adverse effects): Global</td>
<td>NDA submission (in preparation)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

Infectious Diseases: S-649266, S-033188

- **S-649266 (Severe gram-negative infections, injection)**
  - Novel antibiotic for severe gram-negative infections which shows a unique transport mechanism for uptake into bacterial cells
  - Global: Plan to start Phase III study in FY2015

- **S-033188 (Influenza virus infection, oral)**
  - Novel mechanism of action (distinct from neuraminidase inhibitors)
  - Showed potent *in vitro* inhibitory activity against both influenza A virus, including highly pathogenic bird influenza strains, and influenza B virus
  - Target of one time, one dose therapy
  - Safety and PK profile confirmed in Phase I study
  - Designated for “priority review system” on Oct. 27 by the MHLW
    - The review period will be shortened and it will also be given priority for NHI drug price assessment
  - NDA submission in Japan in FY2017, as early as possible

<table>
<thead>
<tr>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>NDA</th>
<th>Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Severe gram-negative infections, Global] S-649266</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[Influenza virus infection, Japan] S-033188</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MHLW: Ministry of Health, Labour and Welfare
New drug candidate for Influenza virus infection with novel mechanism of action

- Inhibit initiation of mRNA synthesis which is the first proliferation step after entry of the influenza virus into the cell → "Cap dependent endonuclease inhibitor"
- Inability to produce proteins essential for virus proliferation inhibits viral granule formation
Applying our know-how in anti-viral drug discovery to discover an oral anti-flu drug candidate, aiming at “innovative First-in-Class”

- Much greater decline in viral load in a mouse model compared to that achieved with a commercially-available comparator
- Showed potent in vitro inhibitory activity against both seasonal and highly pathogenic bird influenza strains resistant to a commercially-available comparator

Expanding and applying our knowledge base built in anti-HIV drug discovery to other viral infections
Continued Improvement of Business Operations
Continued Enhancement of Business Operations

- Resource level to be aligned to growth stage
- Strategic resource allocation

<table>
<thead>
<tr>
<th>Resources</th>
<th>FY2013</th>
<th>Target for FY2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>COGS</td>
<td>289.7</td>
<td>400.0</td>
</tr>
<tr>
<td>R&amp;D expenses</td>
<td></td>
<td>500.0</td>
</tr>
<tr>
<td>SG&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Regulate current amount of resources
- Expansion of resources according to growth potential
- Stable supply/quality and cost-competitiveness
- Creation of FIC, LIC
- Prioritizing and partnering
- Alignments with strategic plan/drivers (GA)
- Effective allocation into strategic products and region (S)
Focus on achieving positive operating income excluding royalties from Crestor® and the HIV franchise

Value creation for all stakeholders and business growth

FIC, LIC compounds

Clear priorities and focused resourcing
- Sales areas: Japan and the US
- Core therapeutic areas: Infectious disease and pain/CNS

Crestor® HIV franchise

Steady income growth from HIV franchise
Stable Crestor® royalty income

Positive operating income excluding Crestor® and HIV
(Business Innovation)

Strengthen pipeline in core therapeutic areas
(Scientific Innovation)

Value creation for all stakeholders
The Medium-Term Business Plan - Shionogi Growth Strategy 2020
Shareholder Return and Investment for Our Future
Maximize enterprise value by balancing three key factors

- **Share the growth**
  - DOE: More than 3.5% in FY2016
  - Further shareholder return

- **Maximize enterprise value**

- **Investment for further growth**

- **Strategic opportunities**
  - Increase flexibility while remaining highly selective in our approach

**Dividend per share**

- FY07: 22
- FY08: 28
- FY09: 36
- FY10: 40
- FY11: 40
- FY12: 42
- FY13: 46
- FY14: 52
- FY15: 60
- FY16: 60 over (Plan)
Reaching the Targets Set for FY2017

Steady growth after modifying the Crestor® royalty structure

* The accounting policy for R&D expenses was changed effective Apr. 1, 2014. Figures for FY2013 have been restated to reflect this change.

** Hypothetical ROE: Based on net income excluding the one-time positive effect of tax expenses.
Forward-Looking Statements

- Forecast or target figures in this material are neither official forecasts of earnings and dividends nor guarantee of target, achievement and forecasts, but present the midterm strategies, goals and visions. Official earnings guidance should be referred to in the disclosure of the annual financial report (kessan tanshin) in accordance with the rules set by Tokyo Stock Exchange.

- Materials and information provided during this presentation may contain so-called “forward-looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.

- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency’s examination period, obtaining regulatory approvals; domestic and foreign healthcare reforms; trend toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.

- For products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.

- Shionogi disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

- This material is presented to inform stakeholders of the views of Shionogi's management but should not be relied on solely in making investment and other decisions.

- You should rely on your own independent examination of us before investing in any securities issued by our company. Shionogi shall accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding or changes of target figures or any other use of this material.

- This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.